Physician profile
Robert M Fetchero
NPI 1285650994
$2,989.20
in general payments reported to CMS, 2019-2025
23 companies · $30.49 in 2025
The $30.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,726 · 2020: $584 · 2021: $221 · 2022: $282 · 2023: $145 · 2025: $30.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $538.96 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $477.50 | 2019-2022 | |
| Allergan, INC. | $274.62 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $266.76 | 2019-2022 | |
| Pfizer INC. | $260.64 | 2019-2023 | |
| Novo Nordisk INC | $192.11 | 2019-2020 | |
| Lilly USA, LLC | $165.89 | 2019 | |
| Astellas Pharma US INC | $123.80 | 2019 | |
| Idorsia Pharmaceuticals US INC | $105.43 | 2022 | |
| Novartis Pharmaceuticals Corporation | $96.62 | 2019 | |
| Amgen INC. | $83.38 | 2019 | |
| Abbvie INC. | $73.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $64.97 | 2019 | |
| Amarin Pharma, INC. | $55.76 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $44.24 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.47 | 2019 | |
| Bridgebio Pharma, INC. | $30.49 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.83 | 2019 | |
| Philips North America LLC | $20.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.71 | 2019 | |
| Daiichi Sankyo INC. | $14.53 | 2020 | |
| Glaxosmithkline, LLC. | $13.47 | 2019 | |
| Sanofi Pasteur INC. | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fetchero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.